Market Cap : 62.55 M | Enterprise Value : 73.29 M | PE Ratio : At Loss | PB Ratio : 1.80 |
---|
NAS:ORGS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:ORGS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Orgenesis has the Growth Rank of 3.
GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:
1. 5-year revenue growth rate, the higher, the better.GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.
Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.
For the Biotechnology subindustry, Orgenesis's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Orgenesis's Growth Rank distribution charts can be found below:
* The bar in red indicates where Orgenesis's Growth Rank falls into.
Thank you for viewing the detailed overview of Orgenesis's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Sidransky David | director | JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205 |
Reithinger Neil | officer: CFO, Treasurer and Secretary | 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260 |
Philips Mario | director | C/O ATMI, INC DANBURY CT 06810 |
Ferber Sarah | officer: Chief Scientific Officer | 17B HAHASKALA STREET TEL AVIV L3 67890 |
Yachin Guy | director | 7 ORCHARD WAY N POTOMAC MD 20854 |
Nanda Ashish | director | 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452 |
Bedoret Denis | officer: See Remarks | 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041 |
Universite Libre De Bruxelles | other: less than 10% | AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050 |
Theodorus Ii Sa | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Theodorus Sca | other: less than 10% | ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070 |
Belenger Olivier | other: less than 10% | DIEWEG, 69 BRUSSELS C9 1070 |
Shvartz Oded | 10 percent owner | 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000 |
Bultot Hugues | director | AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150 |
Buyse Chris Georges Frans | director | BAILLET LATOURLEI 119A BRUSSELS C9 2390 |
Tenne Joseph | officer: CFO Treasurer Secretary | 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511 |
Other Sources
By Seekingalpha 2021-11-06